INTRODUCTION {#s1}
============

Despite decades of efforts, pancreatic cancer (PC) remains a lethal malignancy with a life expectancy of less than 6 months and a 5-year survival rate of around 5%, due to the rapid progression of the disease and early metastasis \[[@R1]\]. The key symptoms associated with PC are usually unremarkable until the cancer has progressed to an advanced stage, and 80% of patients present with locally advanced or metastatic disease at their diagnosis \[[@R2]\]. Hence, the lack of robust, accurate, and non-invasive methods to detect early stages of PC represents an important obstacle to the improvement of outcomes \[[@R3]\].

The only biomarker routinely used for PC in the clinical setting is serum carbohydrate antigen (CA) 19-9, which is evaluated in the follow-up of already diagnosed patients \[[@R4]\]. However, CA19-9 has inadequate sensitivity (∼80%) and specificity (80-90%) to be useful for PC diagnosis \[[@R5]\], and elevated serum concentrations can also be observed in patients with pancreatitis, benign diseases of the hepatobiliary system, or other malignancies of the gastrointestinal tract \[[@R6]\].

Proteomics, i.e., the large-scale study of proteins, is emerging as a powerful technology to assist in the identification of suitable biomarkers of clinical relevance in PC \[[@R7]\]. Historically, the most widely adopted proteomic technique has been two-dimensional electrophoresis (2DE), which offers high resolution for separating proteins within complex protein mixtures \[[@R8]\]. The two-dimensional difference gel electrophoresis (2D-DIGE) variant allows direct comparison of two protein samples on the same gel, combining conventional 2DE with the sensitivity of fluorescent labeling \[[@R9], [@R10]\]. Other protein separation methods used in proteomic studies include gel-free approaches such as liquid chromatography (LC), which offers high sensitivity and yields both quantitative and structural information \[[@R11]\]. Protein separation is followed by an identification phase, commonly using mass spectrometry (MS) \[[@R10]\], which plays a key role in this type of study \[[@R9]\]. More advanced MS techniques, such as surface-enhanced laser desorption/ionization (SELDI-MS) and matrix-assisted laser desorption/ionization (MALDITOF-MS), allow protein profiles to be obtained, but their routine clinical application is hampered by the lack of standardized protocols \[[@R12]\]. Other available techniques include protein or antibody microarrays, which provide high resolution to investigate complex proteomes, and multiplexed enzyme-linked immunosorbent assay (ELISA) \[[@R13]\], whose clinical applicability is favored by the small number of target molecules \[[@R14]\]; however, these techniques depend on the availability of well-characterized antibodies \[[@R13], [@R15]\].

There has also been a call for more precise and less invasive biomarkers from body fluids to encourage their utilization by clinicians and improve the compliance of PC patients \[[@R16]\]. As shown in Figure [1](#F1){ref-type="fig"}, there is a broad spectrum of body fluids enriched with proteins that can be used as potential biomarkers for this lethal disease. The purpose of this review was to describe and discuss key findings published over the past three years in relation to proteome-based biomarkers in body fluids for the detection and evaluation of PC.

![Body fluids for the identification of potential protein biomarkers for pancreatic cancer\
Blood, pancreatic juice, urine, pancreatic cyst fluid and bile are body fluids that contain cancer-derived proteins. These proteins have a high potential as tumor biomarkers and a number of clinical applications for the management of pancreatic cancer patients, such as screening in high-risk populations for pancreatic cancer, early diagnosis, staging of the disease, assessment of tumor resectability and prognosis, prediction of therapy response to guide treatment decisions, and real-time monitoring of patients.](oncotarget-09-16573-g001){#F1}

Proteomic biomarkers of pancreatic cancer in plasma and serum {#s1_1}
-------------------------------------------------------------

Utilization of peripheral blood as a source of circulating proteins for the study of tumor biomarkers is minimally invasive, inexpensive, and highly reproducible \[[@R17]\]. Major efforts have been made to identify new biomarkers for PC in serum or plasma, although this task is complicated by the large number of proteins in blood \[[@R18]\]. Table [1](#T1){ref-type="table"} lists the most recent serum/plasma protein biomarkers proposed for PC.

###### Summary of plasma/serum proteomic biomarkers proposed for the management of pancreatic cancer

  Single biomarker or panel                                                                                 Utility                                                                    Expression pattern^a^        Impact in prognosis   Year        Ref.
  --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------- --------------------- ----------- -----------------------
  IL-6, IL-8, CEA, or HIF-1α                                                                                Prognostic                                                                 All ↑                        Negative              2016        \[[@R19]\]
  IL-6, IL-8, CEA, PDFGFR α, or MUC-1                                                                       Prognosis                                                                  All ↑                        Negative              2016        \[[@R19]\]
  HER2                                                                                                      Predictive for erlotinib                                                   ↑                            Positive              2016        \[[@R19]\]
  IL-11                                                                                                     Diagnostic/prognostic                                                      ↑/↑                          Positive              2014        \[[@R20]\]
  IGF-1R                                                                                                    TNM stage                                                                  ↑                            Negative              2014        \[[@R21]\]
  EPHB3, IL10, IMPDH2, FGF1, ID1, IL2, SELL, and VCAM1                                                      Diagnostic                                                                 ↑, ↑, ↑, ↓, ↓, ↓, ↓, and ↓   \-                    2017        \[[@R14]\]
  ICAM 1                                                                                                    Diagnostic                                                                 ↑                            \-                    2016        \[[@R23]\]
  sCD40L                                                                                                    Diagnostic and prognostic/predictive for FOLFIRINOX or GEM+nabpaclitaxel   ↑ and ↑/↑                    Negative/negative     2014/2016   \[[@R25]\]/\[[@R29]\]
  TGF-b1                                                                                                    Prognostic                                                                 ↑                            Negative              2016        \[[@R32]\]
  LRG1                                                                                                      Diagnostic/prognostic                                                      ↑/↑                          Negative              2015        \[[@R35]\]
  CRP                                                                                                       Prognostic                                                                 ↑/↑                          Negative/negative     2016/2014   \[[@R37]\]/\[[@R38]\]
  Ferritin                                                                                                  Prognostic                                                                 ↑                            Negative              2014        \[[@R38]\]
  C4BPA                                                                                                     Diagnostic                                                                 ↑                            \-                    2016        \[[@R39]\]
  HMGB1                                                                                                     Prognostic                                                                 ↑                            Negative              2016        \[[@R44]\]
  CD80, PK1, IL-29, NRG1-B1, and PDECGF                                                                     Prognostic                                                                 All ↑                        Negative              2015        \[[@R49]\]
  MIC-1                                                                                                     Diagnostic                                                                 ↑                            \-                    2014        \[[@R50]\]
  MIC-1 and ULBP2                                                                                           Diagnostic                                                                 Both ↑                       \-                    2014        \[[@R51]\]
  Cofilin-1                                                                                                 Diagnostic/prognostic                                                      ↑/↑                          Negative              2017        \[[@R12]\]
  sgC1qP                                                                                                    Diagnostic/prognostic                                                      ↑/↑                          Negative              2015        \[[@R61]\]
  PRSS2                                                                                                     Diagnostic                                                                 ↑                            \-                    2015        \[[@R62]\]
  DKK1                                                                                                      Diagnostic/prognostic                                                      ↑/↑                          Negative              2015        \[[@R69]\]
  Survivin                                                                                                  Prognostic                                                                 ↑/↑                          Negative/negative     2014/2015   \[[@R73]\]/\[[@R74]\]
  LDH                                                                                                       Prognostic/predictive for sorafenib                                        ↑/↓                          Negative/positive     2015        \[[@R77]\]
  THBS-1                                                                                                    Diagnostic/prognosis                                                       ↓/↓                          Negative              2016        \[[@R78]\]
  THBS-2 and CA19-9                                                                                         Diagnostic                                                                 Both ↑                       \-                    2017        \[[@R79]\]
  Exosomal protein (CD44v6, Tspan8, EpCAM, MET, CD104) and miRNA (miR-1246, miR-4644, miR-3976, miR-4306)   Diagnostic                                                                 All ↑                        \-                    2015        \[[@R82]\]
  Exosomal GPC1                                                                                             Diagnostic/prognostic                                                      ↑/↑                          Negative              2015        \[[@R83]\]
  CA19-9 and CA242                                                                                          Diagnostic                                                                 Both ↑                       \-                    2015        \[[@R84]\]
  CA19-9, CEA, CA125, and CA242                                                                             Diagnostic                                                                 All ↑                        \-                    2015        \[[@R85]\]
  CA125, CA19-9, and LAMC2                                                                                  Diagnostic                                                                 All ↑                        \-                    2014        \[[@R86]\]
  Prx-1 and CA 19-9                                                                                         Diagnostic/prognostic                                                      Both ↑/both ↑                Negative              2015        \[[@R87]\]
  CA19-9, IGF1, and albumin                                                                                 Diagnostic                                                                 ↑, ↑, and ↓                  \-                    2016        \[[@R88]\]
  CA19-9 and MUC-5AC                                                                                        Diagnostic                                                                 Both ↑                       \-                    2017        \[[@R89]\]
  CA19-9, TFPI, and TNC-FNIII-B                                                                             Diagnostic                                                                 ↑, ↑, and ↑                  \-                    2017        \[[@R90]\]
  TIMP-1, LRG1, and CA19-9                                                                                  Diagnostic                                                                 All ↑                        \-                    2017        \[[@R91]\]
  CA19-9, TIMP1, and Apo-AIV                                                                                Diagnostic                                                                 ↑, ↑, and ↓                  \-                    2017        \[[@R15]\]
  CA19-9, IGFBP2, and IGFBP3                                                                                Diagnostic                                                                 ↑, ↑, and ↓                  \-                    2016        \[[@R92]\]
  C5, IGFBP2, LDHB, PPBP, IGFBP3, and CPN2                                                                  Diagnostic                                                                 ↑, ↑, ↑, ↑, ↓, and ↓         \-                    2016        \[[@R93]\]
  CA19-9, CEA, HGF, OPN, and ctDNA (*KRAS* mutations)                                                       Diagnosis/prognosis                                                        All ↑/all ↑                  Negative              2017        \[[@R95]\]
  Apo-AI and TF                                                                                             Diagnostic/prognosis *(only TF)*                                           Both ↓/both ↓                Negative              2016        \[[@R97]\]
  Apo-AII-ATQ/AT and CA19-9                                                                                 Diagnostic                                                                 ↓ and ↑                      \-                    2015        \[[@R99]\]
  IP-10, IL-6, PDGF, and CA19-9                                                                             Diagnostic                                                                 All ↑                        \-                    2014        \[[@R45]\]
  IL-8, CA19-9, IL-6, and IP-10                                                                             Diagnostic                                                                 All ↑                        \-                    2014        \[[@R45]\]
  IP-10, IL-8, IL-1b, and PDGF                                                                              Diagnostic                                                                 All ↑                        \-                    2014        \[[@R45]\]
  MMP-7 and MMP-12                                                                                          Diagnostic                                                                 Both ↑                       \-                    2014        \[[@R46]\]
  Osteoprotegerin                                                                                           Diagnostic                                                                 ↑                            \-                    2014        \[[@R47]\]
  FGF-10, CXCL11, OSM, GPNMB, and SCF                                                                       Diagnostic                                                                 All ↑                        \-                    2014        \[[@R48]\]
  TNFSF8, CHRDL2, FGF-10, GDF-15, CXCL11, OSM, and SCF                                                      Predictive                                                                 ↓, ↓, ↑, ↓, ↑, ↑ and ↓       Negative              2014        \[[@R48]\]

^a^ Expression pattern observed in pancreatic cancer patients. ↑: upregulated. ↓ downregulated. GEM: gemcitabina.

### Single and multiple biomarkers not including CA19-9 {#s1_1_1}

Phase III trial PA.3 recently reported that several plasma protein-based biomarkers were associated with tumor stage and survival in PC; thus, interleukin (IL)-6, IL-8, carcinoembryonic antigen (CEA), and hypoxia-inducible factor 1-alpha (HIF-1α) levels were related to the prognosis, while increased IL-8, CEA, platelet-derived growth factor receptor alpha (PDFGFRα), and mucin (MUC)-1 concentrations were related to metastasization. It was also observed that the overall survival (OS) of patients with elevated receptor tyrosine-protein kinase erbB-2 (HER2) concentrations was improved by treatment with erlotinib (*vs*. placebo), suggesting a possible role for HER2 as a predictor of the response to this drug \[[@R19]\]. Plasma IL-11 concentrations have also been proposed as a diagnostic, predictive, and prognostic biomarker for PC, with a sensitivity of 97.7% and specificity of 70% \[[@R20]\]. A correlation was also described between plasma insulin-like growth factor 1 receptor (IGF-1R) expression and TNM stage in PC patients, although no significant difference was found between PC patients and healthy controls and no association was observed between survival and this expression \[[@R21]\]. In 2017, Mustafa et al. \[[@R14]\] proposed a biomarker panel for PC diagnosis comprising eight proteins related to cell adhesion, migration, proliferation, and immunity, among others; this panel demonstrated an accuracy of 95% to discriminate between PC patients and healthy individuals but was unable to differentiate between PC and chronic pancreatitis.

In a study of 66 patients with PC, 43 patients with chronic pancreatitis, and 104 healthy controls, Gebauer et al. \[[@R22]\] found that serum epithelial cell adhesion molecule (EPCAM) concentrations, measured by ELISA, offered only low sensitivity (66.7%) and specificity (77.5%) for PC diagnosis. Other authors found that PC and non-cancer cases could be differentiated using serum concentrations of intercellular adhesion molecule 1 (ICAM1), reporting higher sensitivity and specificity for this biomarker than for CA19-9, although it was not possible to discriminate between early and late tumor stages \[[@R23]\]. It should also be taken into account that serum concentrations of ICAM1 and also of tissue inhibitor of metalloproteinase 1 (TIMP1) can be increased by biliary obstruction in cancer patients, with observations of a lower increase in these concentrations in PC patients with *versus* without biliary obstruction \[[@R24]\].

Over the past few decades, advances in immunotherapy have focused attention on immune signaling pathways in the search for cancer biomarkers. In this regard, the soluble form of CD40 ligand (sCD40L), whose serum concentrations have demonstrated prognostic value in PC patients \[[@R25]\], has been implicated in inflammation, angiogenesis, and immune suppression, among other tumor processes, *via* its CD40 receptor \[[@R26]--[@R28]\]. There has been a recent report on the potential of this molecule as a predictive biomarker in metastatic PC patients treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel, observing increased sCD40L concentrations in patients with progressive disease and reduced concentrations in those with a partial response to three months of treatment \[[@R29]\]. CD40 has also been related to transforming growth factor beta 1 (TGF-β1) \[[@R28]\], another key protein implicated in angiogenesis, immune suppression, and cell migration \[[@R30], [@R31]\] and proposed as a prognostic biomarker for PC. Thus, Zhao et al. \[[@R32]\] found higher serum TGF-β1 concentrations in patients with PC than in patients with benign pancreatic disease or healthy controls and observed a correlation of this increase with more advanced tumor stage and metastasis.

Leucine-rich alpha-2-glycoprotein 1 (LRG1), initially identified as a serum inflammatory protein \[[@R33]\], was recently related to angiogenesis *via* the modulation of endothelial TGF-β1 signaling \[[@R34]\]. In another study, higher serum LRG1 concentrations were observed in patients with PC than in those with chronic pancreatitis or healthy individuals and were also associated with disease progression and lymph node metastasis \[[@R35]\].

The association between inflammation and cancer is well documented \[[@R36]\], and serum C-reactive protein (CRP) concentrations have been correlated with the aggressiveness of PC \[[@R37]\]. A phase III clinical trial in 159 unresectable PC patients described a correlation between increased serum ferritin or CRP concentrations and lower OS, although no correlation was found between these biomarkers \[[@R38]\]. Serum concentrations of complement component 4 binding protein alpha (C4BPA) were reported to be altered in patients with PC and other gastroenterological cancers and to allow the detection of early-stage PC and differentiation between PC and other gastrointestinal cancers \[[@R39]\]. Interestingly, C4BPA has binding sites for numerous ligands, including CD40 or CRP, suggesting its implication in inflammatory processes \[[@R40], [@R41]\].

High-mobility group box 1 (HMGB1) has also been proposed as a biomarker for PC. It is involved in multiple signaling pathways (e.g., inflammation, immunity, proliferation, metastasis, and apoptosis), and appears to play contradictory roles in cancer according to its cellular localization \[[@R42], [@R43]\]. Thus, Wu et al. \[[@R44]\] related serum HMGB1 overexpression to shorter OS and progression-free survival in several types of cancer, including PC, whereas other authors proposed a tumor suppressor role for intracellular HMGB1 \[[@R43]\].

Various groups have investigated cytokines as candidate biomarkers for PC due to their implication in numerous cancer-related processes, such as the immune response, inflammation, and metastasis \[[@R45]--[@R48]\]. Torres et al. \[[@R49]\] proposed a prognostic biomarker panel for PC comprising five serum cytokines, including CD80, prokineticin 1 (PK1), IL-29, neuregulin 1 (NRG1-beta1), and thymidine phosphorylase (PDECGF), based on the association between their serum concentrations and a poor prognosis. In a study with 1472 participants, serum macrophage inhibitory cytokine 1 (MIC-1) concentrations were found to be increased in the majority of patients with PC, even in those with early-stage disease and negative for CA19-9, suggesting a role for MIC-1 as a biomarker for PC diagnosis and follow-up \[[@R50]\]. In addition, the detection in serum of MIC-1 in combination with UL16 binding protein 2 (ULBP2) was found to improve the accuracy of differentiation between patients with PC and patients with chronic pancreatitis or healthy individuals \[[@R51]\].

Given the high metastatic and invasive potential of PC \[[@R52]--[@R54]\], research on proteins implicated in these cell processes is of particular interest. Satoh et al. \[[@R12]\] found that serum concentrations of cofilin-1, involved in actin filament dynamics \[[@R55]\] and metastasization \[[@R56]\], were higher in patients with PC than in patients with pancreatitis or healthy individuals; in addition, an association was found between elevated concentrations and a poor prognosis after surgery. The soluble form of the receptor for the globular heads of C1q (sgC1qP) has been linked to inflammation \[[@R57], [@R58]\] and has also proven to be a key regulator of cell proliferation, adhesion, migration, and invasion \[[@R59], [@R60]\]. Higher concentrations of this protein were detected, using sandwich ELISA, in serum and malignant pleural (*n* = 23) and peritoneal (*n* = 27) effusions from metastatic PC patients (*n* = 34) than in healthy controls (*n* = 20) \[[@R61]\]. The same study found an increase in serum sgC1qR concentrations during disease progression in ∼70% of serum samples from the PC patients, in parallel with changes in the tumor biomarkers CEA and CA19-9. In a recent study of 23 patients with PC, 30 patients with pancreatitis, and 35 healthy individuals, a correlation was observed between increased serum concentrations of trypsinogen (PRSS) 2 levels and the presence of PC or pancreatitis, suggesting its possible usefulness as diagnostic biomarker for PC \[[@R62]\].

The tumor microenvironment plays a crucial role in PC progression and contributes to metastasis and therapeutic resistance \[[@R63]\]. In this regard, various groups have reported that dickkopf-1 (DKK1), a soluble inhibitor of Wnt/β-catenin signaling that supports an immunosuppressive environment and epithelial-mesenchymal transition (EMT) \[[@R64], [@R65]\], is frequently overexpressed in cancer \[[@R66]--[@R68]\]. The potential usefulness of this protein as diagnostic and prognostic biomarker for PC was demonstrated by Han et al. \[[@R69]\] in a study of 62 patients with early-stage PC (I/II), 78 with advanced PC (stages III/IV), and 92 PC-free individuals, including healthy individuals and patients with benign pancreatic tumor or chronic pancreatitis. Serum DKK1 concentrations were found to be higher in patients with PC, even in early stages, than in cancer-free individuals, and proved more accurate than CA19-9 for PC diagnosis. Less favorable OS rates were also observed in patients with higher serum DKK1 concentrations.

Survivin, an inhibitor of apoptosis has been implicated in antitumor immunity and EMT \[[@R70], [@R71]\] and proposed as a prognostic indicator in PC \[[@R72]\]. A study of 80 patients with PC and 80 healthy controls found a correlation between increased survivin concentration (by ELISA) and poor OS \[[@R73]\], supported by more recent observations of higher serum survivin concentrations before treatment in patients with PC than in healthy controls and their association with worse outcomes \[[@R74]\].

Hypoxia is frequently observed in the tumor microenvironment of PC, enhancing cell migration and invasion \[[@R75]\]. Biological links among the enzyme lactate dehydrogenase (LDH), hypoxia, and tumor angiogenesis are well established, and LDH concentrations have also been related to resistance to tyrosine kinase inhibitors (TKIs) such as sorafenib \[[@R76]\]. Thus, better progression-free survival (7.6 vs. 2.8 months) and OS (12.7 vs. 5.9 months) outcomes were recorded in sorafenib-treated patients with PC who had lower *versus* higher serum LDH concentrations, indicating the potential usefulness of this enzyme as a prognostic and predictive indicator in this sub-population of patients. In contrast, lower serum LDH concentrations were related to better progression-free survival (3.3 months vs. 2.2 months in patients with high serum LDH concentrations) and OS (8.6 months vs. 5.2 months) \[[@R77]\].

A large-scale study by Jenkinson et al. \[[@R78]\] on the role of the anti-angiogenic molecule thrombospondin (THBS)-1 as diagnostic biomarker for PC analyzed serum samples from patients with PC, chronic pancreatitis, or type 2 diabetes mellitus and from healthy controls and, of particular interest, from PC patients up to 4 years before their diagnosis; results obtained showed a reduction in THBS-1 concentrations up to 24 months before the clinical diagnosis of PC. In contrast, a recent study by Kim et al. \[[@R79]\] found that elevated plasma THBS-2 and CA19-9 concentrations discriminated patients with PC from healthy subjects with 87% sensitivity and 98% specificity. The authors suggested that this discrepancy may result from differences in the history of diabetes between study populations.

A further approach of interest in the proteomic biomarker field is related to exosomes, small membrane vesicles that are secreted by most cell types and are present in the blood and other body fluids \[[@R80], [@R81]\]. They play a key role in intercellular communications, and their potential usefulness in PC detection has recently been proposed \[[@R81]\]. Thus, Madhavan et al. \[[@R82]\] employed a biomarker panel to detect five proteins (CD44 antigen variant 6 \[CD44v6\], tetraspanin-8 \[Tspan8\], EpCAM, proto-oncogene MET \[MET\], and CD104 antigen \[CD104\]) and four microRNAs (miR) (miR-1246, miR-4644, miR-3976 and miR-4306) in circulating exosomes. It achieved 93% specificity to discriminate between PC patients and cancer-free groups (patients with benign pancreatic tumor or chronic pancreatitis and healthy individuals). Strikingly, Melo et al. \[[@R83]\] reported 100% specificity and sensitivity values to distinguish patients with early and late stage PC from cancer-free controls (patients with benign pancreas disease and healthy individuals) based on the detection in circulating exosomes of a single protein molecule, cell surface proteoglycan glypican-1 (GPC1). Although the number of PC precursor lesions studied was limited, the optimal accuracy achieved identifies exosomal GPC1 as a promising biomarker for early PC detection.

Given the low diagnostic usefulness of currently available clinical biomarkers for PC, research efforts have been directed towards the identification of new proteomic biomarkers, with considerable success. However, there is a need to verify the most promising findings in large cohorts and to accelerate their routine clinical application, when justified.

### Biomarker panels including CA19-9 {#s1_1_2}

CA19-9 remains the only FDA-approved PC biomarker and has been included in various biomarker panels in order to complement or surpass its accuracy. Thus, a meta-analysis involving 3497 individuals reported a sensitivity of 89% and specificity of 75% for the combination of CA19-9 and CA242, better than the diagnostic performance of each biomarker individually \[[@R84]\]. In another study in 2015, an accuracy of 92.4% (sensitivity of 90.4% and specificity of 93.8%) was obtained for the combination of serum CA19-9, CEA, CA125, and CA242 concentrations \[[@R85]\]. In the same line, Chan et al. \[[@R86]\] reported a better performance for a biomarker panel consisting of CA125, CA19-9, and laminin subunit gamma 2 (LAMC2) than for CA19-9 alone in the detection of PC and even in the differentiation between early-stage PC and chronic pancreatitis. Other authors found that serum peroxiredoxin-1 (Prx-1) concentrations were higher in patients with PC patients than in healthy controls and that their diagnostic value was higher when used in combination with serum CA19-9 than when each biomarker was considered individually \[[@R87]\]. In 2016, Ferri et al. \[[@R88]\] obtained a sensitivity of 93.6% and specificity of 95% for the combination of CA19-9, insulin-like growth factor 1 (IGF1), and albumin, surpassing the diagnostic value of CA19-9 alone to differentiate between PC and chronic pancreatitis. Likewise, a multicenter study of serum samples from different study groups (early-and late-stage PC, chronic pancreatitis, benign pancreatic disease, and healthy controls) by Kaur et al. \[[@R89]\] found that the diagnostic accuracy of CA19-9 was improved by its combination with MUC-5AC, which achieved 83% sensitivity and 75% specificity to discriminate early-stage PC and cancer-free groups and 83% sensitivity and 83% specificity to discriminate between PC and cancer-free groups.

Balasenthil et al. \[[@R90]\] recently tested the accuracy of a biomarker panel comprising plasma CA19-9, tissue factor pathway inhibitor (TFPI), and an isoform of tenascin C (TNC-FNIII-B) to distinguish early-stage PC from different diseases. They carried out multiple blinded validations in samples from patients with early-stage PC (I/II), chronic pancreatitis, or acute biliary obstruction and from healthy individuals. The accuracy was better with the panel (82%) than with CA19-9 alone (69%) in all early-stage PC cohorts, especially in patients with no history of diabetes or pancreatitis. In this regard, Capello et al. \[[@R91]\] demonstrated that the combination of TIMP1, LRG1, and CA19-9 improved differentiation between patients with early-stage PC and those with benign pancreatic disease or healthy controls in comparison to CA19-9 alone.

Another panel proposed for PC detection was based on serum CA19-9, apolipoprotein (Apo)-AIV, and TIMP1 and obtained a sensitivity of 86% and specificity of 90% in the differentiation of early-stage PC from pancreatitis, higher values than achieved using CA19-9 alone (71% and 90%, respectively) \[[@R15]\]. Yoneyama et al. \[[@R92]\] observed that the diagnostic value of CA19-9 to detect early-stage PC was improved when combined with insulin-like growth factor binding protein (IGFBP) 2 and IGFBP3. Likewise, Kim et al. \[[@R93]\] recently reported that a biomarker panel comprised of six proteins, including IGFBP2 and IGFBP3, had a high capacity to distinguish patients with intraductal papillary mucinous neoplasm (IPMN) from controls (healthy individuals or with other benign disease).

An alternative approach to biomarker discovery is the study of combinations of different types of molecule, including genes, proteins, and RNAs, among others, given that all affect the development of cancer \[[@R13], [@R94]\]. A recent study of plasma samples from 221 patients with resectable PC and 182 healthy controls tested combinations of genomic and proteomic biomarkers \[[@R95]\]; the authors reported sensitivity of \>60% and specificity of ∼100% for early PC detection using a combination of circulating tumor DNA (ctDNA) (mutations in KRAS proto-oncogene, GTPase \[*KRAS*\]), with protein biomarkers (CA19-9, CEA, hepatocyte growth factor \[HGF\], and osteopontin \[OPN\]).

Although CA19-9 is the gold standard for the management of PC, this serum antigen is not expressed in over 10% of the general population, who are Lewis-negative \[[@R96]\]. Lin et al. \[[@R97]\] analyzed serum samples from CA19-9-negative (*n* = 34) and -positive (*n* = 44) patients with PC and healthy controls (*n* = 36) and reported the diagnostic usefulness of Apo-AI and transferrin (TF) concentrations as biomarkers in CA19-9-negative PC patients. Another group investigated plasma/serum concentrations of various Apo-AII isoforms in this context and found a significant decrease in Apo-AII-ATQ/AT concentrations in patients with PC compared with healthy controls \[[@R98]\]. The same group recently developed an antibody-based proteomic approach (using ELISA) for clinical applications, which was tested in a large-scale study with 1156 participants, including 151 patients with PC stage I/II \[[@R99]\]. According to the results, a greater accuracy to discriminate patients with early-stage PC from healthy controls and to identify patients at high risk for PC was achieved by using CA19-9 in combination with Apo-AII-ATQ/AT than by using CA19-9 alone.

The inclusion of CA19-9 in biomarker panels is appealing because it is the "gold standard" for PC diagnosis. One potentially valuable clinical approach could be to continue managing the disease using this well-known biomarker but combine it with others that improve its sensitivity and specificity, increasing the accuracy.

Proteomic biomarkers of pancreatic cancer in urine {#s1_2}
--------------------------------------------------

A major advantage of urine as source of biomarkers is that it can be obtained non-invasively; however, its separation from the tumor by the circulation and kidneys represents an important limitation \[[@R100]\]. Nevertheless, recently various groups have proposed certain proteins present in urine as biomarkers for PC (Table [2](#T2){ref-type="table"}).

###### Summary of urinary proteomic biomarkers proposed for the management of pancreatic cancer

  Single biomarker or panel        Utility                      Expression pattern^a^   Impact in prognosis   Year   Ref.
  -------------------------------- ---------------------------- ----------------------- --------------------- ------ -------------
  LYVE-1, REG-1-alpha, and TFF-1   Diagnostic                   All ↑                   \-                    2015   \[[@R101]\]
  D-dimer                          Preoperative resectability   ↑                       Negative              2014   \[[@R102]\]

^a^ Expression pattern observed in pancreatic cancer patients. ↑: upregulated. ↓ downregulated.

A study of urinary proteomes in samples from patients with PC or chronic pancreatitis and healthy controls selected the following biomarkers as candidates for the detection of early-stage PC: lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), regenerating gene (REG)-1-alpha, and trefoil factor (TFF)-1. These biomarkers showed areas under the curve (AUC) between 0.89 and 0.92 (192 samples from PC patients *vs*. 87 from healthy controls) and between 0.90 and 0.93 (71 samples from PC stage I/II patients *vs*. 87 from healthy controls) and were proposed as a new panel of biomarkers for early PC detection in urine samples \[[@R101]\].

Other authors measured concentrations of D-dimers, the final degradation products of cross-linked fibrin, in 64 patients with potentially resectable pancreatic head tumor and without detectable venous thrombosis in order to predict the preoperative resectability of the tumor. They observed higher average D-dimer values in the peripheral and in portal blood of patients with unresectable PC but found no significant differences in their bile and urine samples. They concluded that a tumor in patients with high D-dimer levels that appears resectable by imaging techniques can be considered unresectable due to occult hepatic metastases \[[@R102]\].

Urine is an ideal fluid for diagnostic screening tests, because a large volume is readily available from patients in a wholly non-invasive manner. Further research is therefore warranted on the identification and validation of potential urinary biomarkers of PC.

Proteomic biomarkers of pancreatic cancer in pancreatic juice {#s1_3}
-------------------------------------------------------------

Samples of pancreatic juice are usually collected directly from the pancreatic duct during surgery or by endoscopic retrograde cholangiopancreatography-based suction, an invasive procedure that may have adverse effects \[[@R103]\]. Hence, pancreatic juice is not an ideal matrix for screening; however, its main advantage as a source of potential biomarkers is that is in direct contact with the pancreas and therefore enriched with numerous proteins derived from the tumor \[[@R104]\]. Various researchers have attempted to identify PC biomarkers in pancreatic juice (Table [3](#T3){ref-type="table"}).

###### Summary of pancreatic juice proteomic biomarkers proposed for the management of pancreatic cancer

  Single biomarker or panel                                                       Utility      Expression pattern^a^        Impact in prognosis   Year   Ref.
  ------------------------------------------------------------------------------- ------------ ---------------------------- --------------------- ------ -------------
  AMYP, PRSS1, GP2-1, CCDC132, REG-1-Alpha, REG-1-Beta, REG-3-Alpha, and LIPRP2   Diagnostic   ↑, ↑, ↑, ↑, ↑, ↑, ↑, and ↓   \-                    2014   \[[@R105]\]
  Mucins and S100A8 or S100A9                                                     Prognostic   All ↑                        Negative              2014   \[[@R106]\]
  MUC-1                                                                           Diagnostic   ↑                            \-                    2015   \[[@R107]\]
  CPA5, LIPRP1, KLK1, HBD, and TTR                                                Diagnostic   ↓, ↓, ↓, ↑, and ↑            \-                    2015   \[[@R108]\]

^a^ Expression pattern observed in pancreatic cancer patients. ↑: upregulated. ↓ downregulated.

In an LC-MS/MS study of the proteome of pancreatic ductal fluid from patients with PC, pancreatitis, or IPMN and healthy controls \[[@R105]\], higher concentrations of pancreatic amylase (AMYP), PRSS1, glycoprotein GP2-1, coiled-coil domain-containing protein 132 (CCDC132), REG-1-Alpha, REG-1-Beta, and REG-3-Alpha, and lower concentrations of pancreatic lipase-related protein (LIPRP) 2 were observed in samples from patients with cancer than in those from healthy individuals. Most of the proteins identified were secreted proteins (81%), related to proteolysis (52%) or metabolic processes (29%). However, only 12 samples were assessed for protein identification and quantification in this study (three samples for each diagnosis). Another study, also limited by its small sample size, described high concentrations of mucins and S100A8 or S100A9 inflammatory proteins in ductal fluid as predictors of poor survival and suggested that pancreatic ductal fluid was a promising matrix for the identification of prognostic biomarkers \[[@R106]\].

Matsumoto et al. \[[@R107]\] evaluated MUC-1, a membrane-associated mucin, in pancreatic juice samples from 39 patients with malignant pancreatic mass and 31 patients with benign pancreatic mass in order to study the clinical impact of this biomarker. They observed higher MUC-1 concentrations in patients with PC or intraductal papillary mucinous carcinoma (IPMC) than in those with inflammatory pancreatic lesion or IPMN, reporting sensitivity, specificity, and accuracy values for MUC-1 (with a 16 U/mL cut-off) of 79.5%, 64.5%, and 72.9%, respectively.

Finally, in a study of intraoperative and postoperative pancreatic juice samples, a subgroup of 11 surgically-treated patients (9 with PC and 2 with non-malignant neoplasm) showed a higher expression of the biomarkers carboxypeptidase A5 (CPA5), inactive LIPRP1 and kallikrein 1 (KLK1) in those with non-malignant disease and a higher expression of hemoglobin subunit delta HBD and transthyretin (TTR) in those with PC. Moreover, differential expression of nine proteins was observed between the six patients who underwent neoadjuvant chemotherapy and the five who did not, with five of the proteins (pancreatic triacylglycerol lipase \[PNLIP\], inactive LIPRP1, LIPRP2, chymotrypsinlike elastase family member 3B \[CELA3B\], and carboxypeptidase A1 \[CPA1\]) being related to up-front surgery and the other four (Apo-B, fibronectin \[FN1\], α-2-HS-glycoprotein \[AHSG\], and inter-α-trypsin inhibitor heavy chain H1 \[ITIH1\]) to chemotherapy \[[@R108]\].

Given that pancreatic juice collection is invasive, this body fluid is far from ideal for diagnostic screening in general populations. Nevertheless, it contains a large number of pancreatic proteins, i.e., potential biomarkers, and may therefore prove useful for the prognosis and management of individuals at high risk of PC.

Proteomic biomarkers of pancreatic cancer in other body fluids {#s1_4}
--------------------------------------------------------------

The proteome of body fluids varies substantially depending on the proximity of the fluid to the PC and its physiological nature; therefore, proteins that are candidate PC biomarkers may be enriched in some fluids but not in others \[[@R109]\]. This variability has prompted some research groups to search for potential biomarkers in other less conventional body fluids (Table [4](#T4){ref-type="table"}).

###### Summary of proteomic biomarkers in body fluids proposed for the management of pancreatic cancer

  Single biomarker or panel      Sample       Utility      Expression pattern^a^   Year   Ref.
  ------------------------------ ------------ ------------ ----------------------- ------ -------------
  Mucin                          Cyst fluid   Diagnostic   ↑                       2014   \[[@R113]\]
  Mucin                          Cyst fluid   Diagnostic   ↑                       2014   \[[@R114]\]
  MUC-5AC and MUC2               Cyst fluid   Diagnostic   Both ↑                  2017   \[[@R115]\]
  MUC-5AC and PSCA               Cyst fluid   Diagnostic   Both ↑                  2017   \[[@R115]\]
  AFM, REG-1-A, PIGR, and LCN2   Cyst fluid   Diagnostic   ↓, ↑, ↑, and ↑          2015   \[[@R111]\]
  sLR11                          Bile         Diagnostic   ↑                       2016   \[[@R117]\]

^a^ Expression pattern observed in pancreatic cancer patients. ↑: upregulated. ↓ downregulated.

There is no risk of the malignant transformation of non-mucinous pancreatic cysts, whereas mucinous cysts have the potential to progress to invasive PC \[[@R110]\]. The diagnostic accuracy of current clinical techniques to distinguish between these types of cyst lesion is not satisfactory \[[@R111], [@R112]\]; therefore, the identification of biomarkers for this purpose may represent a good strategy to improve OS outcomes in these patients. Streitz et al. \[[@R113]\] used one-dimensional SDS polyacrylamide gel electrophoresis (1D-SDS PAGE) and a dual staining method to analyze cyst fluid mucin in 28 patients and reported high sensitivity and specificity (95% and 100%, respectively) to differentiate between mucinous and non-mucinous pancreatic cysts. Another study on the proteomic profile of 79 patients reported that mucinous cysts were detected with 97.5% accuracy and malignant transformation was predicted with 89.7% accuracy \[[@R114]\]. More recently, the same authors described an increased accuracy of 97% for a proteomic panel consisting of MUC-5AC and MUC-2 to discriminate between premalignant/malignant pancreatic cystic lesions and benign disease, and accuracy values of 96% and 95% for the combination of MUC-5AC with prostate stem-cell antigen (PSCA) to identify high-grade dysplasia/cancer and malignant/severely dysplastic lesions, respectively \[[@R115]\], the results for both panels were superior to those obtained with existing diagnostic tools. In the same line, Park and colleagues \[[@R111]\] recently described a panel of four proteins that discriminated mucinous from non-mucinous cysts with an accuracy of 93%.

The complex composition of bile has hampered the search for PC biomarkers in this fluid, but technological advances in proteomics have now made this feasible. Thus, a study of bile samples from 24 patients by Navaneethan et al. \[[@R116]\] detected the differential abundance of certain proteins among participants with holangiocarcinoma, PC, primary sclerosing cholangitis, and benign disease. They reported increased bile concentrations of 18 proteins, including S100A8 and S100A9, and decreased concentrations of 30 others, including TFF-2, in the patients with malignant disease, and found protein similarity between bile and plasma. More recently, Terai and colleagues \[[@R117]\] proposed bile soluble sortilin related receptor 1 (sLR11) concentrations as a potential biomarker for PC and biliary tract cancer, based on its significantly higher concentrations in the cancer patients than in those with benign disease in their study population of 72 patients.

The collection of pancreatic juice is not risk-free, and Rocker et al. \[[@R103]\] proposed a promising approach to overcome this drawback based on the secretion of juice into the bowel. They studied the effluent of whole-gut lavage performed for colonoscopy and found that most of the proteins in this fluid were of pancreatic origin. Given that colonoscopy is a routine clinical procedure, this novel approach opens up the possibility of a double-screening procedure for pancreatic and colorectal lesions.

CONCLUSIONS {#s2}
===========

PC is one of the most lethal tumors, being the fourth most frequent cause of death from cancer worldwide. The possibility of successful treatment is known to increase with earlier diagnosis, but its detection at an early stage remains challenging, and there is a need for more sensitive and specific biomarkers. Despite advances in the identification of useful biomarkers for many types of cancer, the same success has yet to be achieved for PC. However, the development of a proteomic approach offers new hopes for the discovery of novel protein biomarkers for PC that do not require an invasive procedure.

Liquid biopsies have become more common, and numerous authors have studied the clinical relevance of multiple biomarkers in various body fluids. In some studies, conventional biomarkers have been combined with new molecules to increase their usefulness. The large number of genetic alterations that can underlie PC and the high heterogeneity among patients suggest that significantly more valuable results can be obtained with panels of multiple proteins than with a single biomarker.

Proteomic studies have identified proteins with high potential diagnostic and/or prognostic value in PC and have published abundant information on proteome aberrations that could potentially be therapeutic targets. Results have been promising, but their translation from research laboratories to the clinical setting is disappointingly slow. Hence, there is an urgent need for large-scale validation studies and for close collaboration between researchers and clinicians to develop clinical trials that could accelerate the clinical implementation of useful biomarkers.
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